(Q42204833)

18 October 2017

title

Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine (English)

1 reference

18 October 2017

0 references

8

Egil Lien

1 reference

18 October 2017

Kimberly Pouliot

1

1 reference

18 October 2017

Rachel Buglione-Corbett

2

1 reference

18 October 2017

Robyn Marty-Roix

3

1 reference

18 October 2017

Sara Montminy-Paquette

4

1 reference

18 October 2017

Kim West

5

1 reference

18 October 2017

Shixia Wang

6

1 reference

18 October 2017

Shan Lu

7

1 reference

18 October 2017

language of work or name

English

0 references

publication date

18 July 2014

1 reference

18 October 2017

1 reference

18 October 2017

volume

32

1 reference

18 October 2017

issue

39

1 reference

18 October 2017

page(s)

5049-5056

1 reference

Mechanism of action of licensed vaccine adjuvants

18 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

The perfect mix: recent progress in adjuvant research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Towards an understanding of the adjuvant action of aluminium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Lipid A and immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Lipid A and liposomes containing lipid A as antigens and adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

TLR4-mediated pro-inflammatory dendritic cell differentiation in humans requires the combined action of MyD88 and TRIF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

In vivo and in vitro induction of IL-6 by Quillaja saponaria molina triterpenoid formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

MD-2-mediated ionic interactions between lipid A and TLR4 are essential for receptor activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

The attenuated inflammation of MPL is due to the lack of CD14-dependent tight dimerization of the TLR4/MD2 complex at the plasma membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Toll-like receptor 4 is a sensor for autophagy associated with innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Innate and adaptive immunity through autophagy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Enhancement of immune response to a DNA vaccine against Mycobacterium tuberculosis Ag85B by incorporation of an autophagy inducing system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.010

10.1016/J.VACCINE.2014.07.010

7 January 2021

Identifiers

DOI

1 reference

18 October 2017

1 reference